Shalini Shenoy, M.D.  shenoy@wustl.edu

Profile picture
Professor of Pediatrics, Washington University in St. Louis
Hematology and Oncology

phone: (314) 454-6018

Clinical Interests

Dr. Shenoy's research interests are focused on stem cell transplants for non-malignant disorders, reduced intensity transplants, and the immunologic mechanisms of graft rejection, graft versus host disease (GVHD), and immune reconstitution following stem cell transplantation (SCT). These efforts are directed at making SCT safer and better tolerated by reducing associated toxicities, especially as it relates to non-malignant disorders such as hemoglobinopathy. She is the Prinicipal Investigator of national trials of unrelated donor transplantation for severe sickle cell disease termed the SCURT Trial (Bone Marrow Transplant Clinical Trials Network 0601, NHLBI) and thalassemia termed the URTH Trial (Thalassemia Clinical Research Network, NHLBI). Other clinical trials for additional non-malignant disorders such as bone marrow failure syndromes using alternative and minimally mismatched donors are also underway.

Education

  • MBBS, Kasturba Medical College1981
  • MD, Kasturba Medical College1985
  • MD, Louisiana State University Medical Center1991
  • MD, Washington University in St. Louis1996

Training

  • Residency in Pediatrics, Kasturba Medical College1982 - 1985
  • Residency in Pediatrics, Louisiana State University Medical Center1989 - 1991
  • Fellowship in Pediatric Hematology Oncology, Washington University in St. Louis1992 - 1996

Licensure and Board Certification

  • MO, MD
  • Pediatric Hematology Oncology

Honors and Awards

  • American Society of Histocompatibility and Immunogenetics Scholar Award2001 - 2001
  • Fred Saunders Lecture Award, CBMTG2012 - 2012
  • Teresa J Vietti MD Scholar in Pediatrics, Washington University School of Medicine in St. Louis2014 - Pres

Recent Publications view all (323)


  1. Bilateral native nephrectomies for severe hypertension in children with stage 5 chronic kidney disease leads to improved BP control following transplantation. Pediatr Nephrol. 2020. PMID:32885281 
  2. Cardiac Magnetic Resonance Feature Tracking Global Longitudinal Strain and Prognosis After Heart Transplantation. JACC Cardiovasc Imaging. 2020;13(9):1934-1942. PMID:32563650 
  3. Esophageal Evaluation for Patients Undergoing Lung Transplant Evaluation: What Should We Do for Evaluation and Management. Gastroenterol Clin North Am. 2020;49(3):451-466. PMID:32718564 
  4. Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. J Clin Immunol. 2020. PMID:32860171 
  5. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Adv. 2020;4(16):3894-3899. PMCID:PMC7448594  PMID:32813873 
  6. Chimerism in the Realm of Hematopoietic Stem Cell Transplantation for Non-malignant Disorders-A Perspective. Front Immunol. 2020;11:1791. PMCID:PMC7438804  PMID:32903736 
  7. HLA-mismatched microtransplantation for relapsed or refractory acute myeloid leukemia as a bridge to allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55(8):1684-1686. PMID:31784688 
  8. Peri-operative administration of tranexamic acid in lower limb arthroplasty: a multicentre, prospective cohort study. Anaesthesia. 2020;75(8):1050-1058. PMID:32500530